Rhythm Pharmaceuticals, Inc. RYTM Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $60.11M+5.0% | $57.25M+11.6% | $51.3M+5.8% | $48.5M+48.3% | $32.7M-21.8% | ||
| $7.16M+49.0% | $4.8M-12.7% | $5.5M-0.8% | $5.54M+51.9% | $3.65M-3.7% | ||
| $52.96M+1.0% | $52.45M+14.5% | $45.8M+6.6% | $42.96M+47.8% | $29.06M-23.6% | ||
| 88.1%-3.5pp | 91.6%+2.3pp | 89.3%+0.7pp | 88.6%-0.3pp | 88.8%-2.1pp | ||
| $41.73M-0.7% | $42.03M-8.7% | $46.03M+8.8% | $42.31M+14.4% | $36.97M-10.2% | ||
| $63.59M+10.6% | $57.48M+9.6% | $52.43M+14.1% | $45.95M+17.6% | $39.09M+2.5% | ||
| $112.47M+7.8% | $104.32M+0.4% | $103.95M+10.8% | $93.8M+17.7% | $79.71M-4.1% | ||
| -$52.36M-11.3% | -$47.06M+10.6% | -$52.65M-16.2% | -$45.3M+3.6% | -$47M-13.9% | ||
| -87.1%-4.9pp | -82.2%+20.4pp | -102.6%-9.3pp | -93.4%+50.3pp | -143.7%-45.1pp | ||
| $4.58M-0.7% | $4.62M-2.7% | $4.74M-18.5% | $5.82M+7.5% | $5.41M-0.7% | ||
| $3.55M-13.0% | $4.09M-5.6% | $4.33M+33.5% | $3.24M-10.9% | $3.64M+3.5% | ||
| -$2.73M-478% | -$473K-238% | -$140K+86.0% | -$999K+58.6% | -$2.41M— | ||
| -$55.09M-15.9% | -$47.54M+10.0% | -$52.79M-14.0% | -$46.3M+6.3% | -$49.42M-13.9% | ||
| $545K— | $0-100% | $111K-67.1% | $337K+321% | $80K— | ||
| -$55.64M-17.1% | -$47.51M+10.2% | -$52.9M-13.4% | -$46.63M+5.8% | -$49.5M-14.3% | ||
| -92.6%-9.6pp | -83%+20.2pp | -103.1%-7.0pp | -96.1%+55.2pp | -151.4%-47.9pp | ||
| -$0.83-13.7% | -$0.73+11.0% | -$0.82-9.3% | -$0.75+7.4% | -$0.81-12.5% | ||
| -$0.83-13.7% | -$0.73+11.0% | -$0.82-9.3% | -$0.75+7.4% | -$0.81-12.5% | ||
| 68M+4.6% | 65M-1.9% | 66.3M+4.0% | 63.7M+1.0% | 63.1M+3.4% | ||
| 68M+4.6% | 65M-1.9% | 66.3M+4.0% | 63.7M+1.0% | 63.1M+3.4% | ||
| -$54.4M-11.7% | -$48.71M+8.0% | -$52.96M-5.5% | -$50.18M+1.3% | -$50.83M-15.4% | ||
| $1.1M-17.1% | $1.33M-3.1% | $1.38M+1.9% | $1.35M+2.0% | $1.32M-1.3% | ||
| $3.55M-13.0% | $4.09M-5.6% | $4.33M+33.5% | $3.24M-10.9% | $3.64M+3.5% | ||
| -$544K-557% | $119K-75.6% | $488K+625% | -$93K-830% | -$10K+97.6% | ||
| $1.78M— | $0-100% | $834K+140% | -$2.1M-105,100% | -$2K-100% | ||
| -$1.7M-3,089% | $57K-79.2% | $274K-82.6% | $1.58M+345% | -$644K-298% | ||
| $60.11M+5.0% | $57.25M+11.6% | $51.3M+5.8% | $48.5M+48.3% | $32.7M-21.8% | ||
| -$52.36M-11.3% | -$47.06M+10.6% | -$52.65M-16.2% | -$45.3M+3.6% | -$47M-13.9% | ||
| —— | —— | —— | —— | —— | ||
| -$52.36M-11.3% | -$47.06M+10.6% | -$52.65M-16.2% | -$45.3M+3.6% | -$47M-13.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s revenue?
- Rhythm Pharmaceuticals, Inc. (RYTM) generated $217.2M in revenue over the trailing twelve months, up 58.7% year over year.
- Is Rhythm Pharmaceuticals, Inc. profitable?
- Rhythm Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $202.7M over the trailing twelve months, a -93.3% net margin.
- What are Rhythm Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 89.4% and operating margin is -90.9%, with a -93.3% net margin.
- What is Rhythm Pharmaceuticals, Inc.'s earnings per share?
- Rhythm Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-3.13.
- Where does Rhythm Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Rhythm Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
